Stereotactic biopsy with contrast-enhanced mammography: the initial Australian experience.

Introduction: Contrast-enhanced mammography (CEM) and MRI detect 'contrast-only' lesions (COLs) occult on standard breast imaging (ultrasound and conventional mammography). Until recently, MRI was the only reliable method of biopsy. This study presents the first Australian experience with CEM-guided biopsy (CEMBx) and the lessons learnt.

Malignancy mimic: Suspicious mammographic and sonographic findings post-vacuum-assisted excision biopsy.

Vacuum-assisted excision biopsy (VAEB) provides a safe alternative to surgical excision for selected (low-risk) B3 breast lesions. We report a case of imaging findings that mimicked malignancy in a patient one year post-VAEB. Awareness of this entity is important to prevent misdiagnosis and unnecessary surgical excision.

Mammary schistosomiasis: A rare case.

Schistosomiasis is prevalent in some developing countries; however, it does not commonly affect the breast. Mammary schistosomiasis may present as suspicious microcalcification or a mass on mammography. Image-guided biopsy is necessary to exclude malignancy and identify calcified Schistosoma ova on histology.

Diagnostic concordance among pathologists interpreting breast core biopsies on secondary review over a 1-year period at an Australian tertiary hospital.

This study provides data on the diagnostic concordance between initial and review diagnoses of all breast core biopsy cases at a single tertiary hospital in Western Australia over a 1-year period. A retrospective review of all breast core biopsy cases between January 1 and December 31, 2016, was carried out at PathWest, Fiona Stanley Hospital in Perth, Western Australia. Each biopsy is reported by a single pathologist and then reviewed within 1 week by a panel of intradepartmental subspecialist breast pathologists, who either agree with the original diagnosis, have a minor discordant diagnosis, or a major discordant diagnosis.

Practical issues concerning the implementation of Ki-67 proliferative index measurement in breast cancer reporting.

Commercial molecular tests which rely heavily on proliferation markers to stratify breast cancer are in increasing demand, but are expensive and not widely available. There is heightened interest in the use of Ki-67 immunohistochemistry as a marker of proliferation. This study sought to examine practical issues in the incorporation of Ki-67 measurement into breast cancer reporting.

Suspicious mammographic parenchymal abnormalities that are occult at ultrasonography.

Aim: The study aims to ascertain the significance of ultrasonically occult but mammographically suspicious parenchymal abnormalities, detected at screening mammography.

Method: A retrospective analysis was made on BreastScreen Western Australia data from January 2004 to December 2009. The study group included cases with a mammographic parenchymal abnormality, a negative ultrasound scan and a biopsy under stereotactic guidance.